1, the effect of SLT diminishes in time; how fast does IOP get below target IOP after SLT? 2, is a repeat SLT effective to get/keep IOP under target IOP? 3, is there a racial difference in effect of SLT?
ID
Bron
Verkorte titel
Aandoening
Glaucoma, laser treatment, glaucoom, laser behandeling
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
time to redo SLT
Achtergrond van het onderzoek
SLT has proven to be a viable alternative for medication in the treatment of glaucoma patients. Like argon laser trabeculoplasty, its effect seems to lower in time. Its repeatability is therefore important. We ai mto investigate how long it takes for the efect of SLT wears off and whether a second SLT is as effective as the first SLT to lower IOP.
Doel van het onderzoek
1, the effect of SLT diminishes in time; how fast does IOP get below target IOP after SLT?
2, is a repeat SLT effective to get/keep IOP under target IOP?
3, is there a racial difference in effect of SLT?
Onderzoeksopzet
baseline, 1 week, 3, 6, 12, 18, 24, 30, 36, 42, 48, 60 months
Onderzoeksproduct en/of interventie
1, redo of SLT when target IOP is exceeded by more than 2 mmHg when IOP was controlled at least 6 months after intial SLT
2, control group under medication
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patients with ocular hypertension or open angle glaucoma.Other types of glaucoma than open angle glaucoma, corneal disease that inhibit good visualization of the trabecular meshwork, taking of systemic or local steroids.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Other types of glaucoma than open angle glaucoma, corneal disease that inhibit good visualization of the trabecular meshwork, taking of systemic or local steroids.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6144 |
| NTR-old | NTR6299 |
| Ander register | : NTR5417 |
Samenvatting resultaten
DOI 10.1186/s40662-016-0041-y
De Keyser M. Power is not energy. Letter to the Editor. Journal of Glaucoma, May 5, 2016. Doi:10.1097/IJG.0000000000000432
De Keyser M, De Belder M, De Groot V. Randomized prospective study of the use of anti-inflammatory drops after selective laser trabeculoplasty. Journal of Glaucoma, 26(2), e22-e29.doi:10.1097/IJG.0000000000000522.
De Keyser M, De Belder M, De Groot V. Selective laser trabeculoplasty in pseudophakic and phakic eyes: a prospective study. International Journal of Ophthalmology, 10;4:2017.
De Keyser M, De Belder M, De Groot V. Prospective study on the effect of selective laser trabeculoplasty in normal tension glaucoma. International Journal of Ophthalmology and Eye Science, S1:008, 36-41, 2016. IJOES-2332-290X-S1-008
De Keyser M, De Belder M, De Groot V. Treatment-related quality of life in glaucoma patients: comparison between selective laser trabeculoplasty and medication. International Journal of Ophthalmology, 10; 4: 2017.
De Keyser M, De Belder M, De Belder J, De Groot V. Effect of selective laser trabeculoplasty in glaucoma patients with high or low central corneal thickness. Insights in Ophthalmology, vol 1, 1:3, 2017.
De Keyser M, De Belder M, De Belder J, De Groot V. Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients. In submission.